CME Presentations

Heart Failure


Presentations


Speakers


CME Information

Reducing Mortality and Hospitalization in Heart Failure: Research Updates and Novel Treatments for HFpEF and HFrEF


Global LogoPQH Logo

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Describe the mechanism of action of newly approved agents for the management of HF and how it relates to HF pathophysiology
  • Identify candidates for newer HF agents with efficacy in reducing mortality and hospitalization rates in patients with HF with HFpEF
  • Discuss recent clinical trial data from emerging agents that have demonstrated efficacy in the treatment of HFpEF and HFrEF
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC in collaboration with the American Society of Preventative Cardiology (ASPC).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation, Merck Sharp & Dohme Corporation, and AstraZeneca.

DATE OF RELEASE/EXPIRATION

October 20, 2020 – October 20, 2021

TARGET AUDIENCE

The educational design of this activity addresses the needs of cardiologists, nephrologists, primary care physicians, internists, nurse practitioners, physician assistants, pharmacists, and nurses involved in the management and treatment of patients with heart failure.

STATEMENT OF NEED/PROGRAM OVERVIEW

Despite advances in heart failure (HF) treatment during the past decade, this disease remains associated with high rates of morbidity, hospitalizations, and mortality, in addition to marked health care costs. Although women with HF live longer than men, they have a poorer quality and worse signs and symptoms of the disease. Women with HF also receive suboptimal treatment compared with men, illustrating a remediable disparity in care.

The evaluation and treatment of patients diagnosed with HF with reduced ejection fraction (HFrEF) represents a great challenge in both the general population and among elderly individuals who are the most vulnerable to this difficult-to-treat condition, partly because of the large number of associated comorbidities that such patients present with. Diagnosis of HF in women is also challenging because of its presentation. Uptake and optimization of HF pharmacotherapies is poor overall and is markedly low for newest agents. Disease-modifying medications have limited efficacy among people with heart failure with preserved ejection fraction (HFpEF). Fortunately, research is rapidly emerging on novel therapies for both HFpEF and HFrEF, and recently, anti-diabetes agents have shown cardiovascular (CV) benefits.

This educational initiative addresses guideline-concordant approaches to promote guideline-concordant treatment of HF and optimization of pharmacotherapy. Outcome analyses from a 2019 education series held by PQHE found that while the vast majority of respondents reported improved understanding or behavior change regarding the learning objectives, many participants could still not identify guideline-concordant therapies in case-based questions. Thus, an improved understanding of treatment guidelines, latest clinical trial data in a variety of patients populations with HF, including women and those with HFpEF, and enhanced ability to address barriers to guideline-directed medical therapy for HF are clearly needed among cardiologists, cardiology allied health professionals, and primary care physicians to reduce mortality rates and improve quality of life of people with HF.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TERM OF OFFERING

This activity was released on October 20, 2020 and is valid for 12 months. Requests for credit must be made no later than October 20, 2021.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

SYSTEM REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
James L. Januzzi, MD
Hutter Family Professor of Medicine, Harvard Medical School
Cardiology Division, Massachusetts General Hospital
Boston, MA
Consultant/Independent Contractor:
Abbott Laboratories, Novartis, Janssen Pharmaceutica, Roche

Grant/Research Support:
Novartis, Roche

Other/Royalty:
Endpoint Committees: Abbott Laboratories, AbbVie Inc., Amgen Inc., Bayer, CVRx, and Takeda Pharmaceutical Company
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Division Chief of Cardiology
University of Arizona-Phoenix-Professor of Medicine
Phoenix, AZ
Nothing to disclose
Alison L. Bailey, MD, FACC, FAACVPR
Chief of Cardiology
Centennial Heart at Parkridge HCA Healthcare,
Chattanooga, TN
Advisory Board: Bayer Pharmaceutics company

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Bridget Griffin Nothing to disclose

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.

Heart Failure: Exploring Gender Differences in its Presentation and Management


PIM LogoPQH Logo

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Demonstrate improved ability to incorporate guideline-concordant treatment strategies into the individualized care of patients with heart failure (HF) with reduced and preserved ejection fraction
  • Discuss gender differences in HF presentation and etiology and implications for current management
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC in collaboration with the American Society of Preventative Cardiology (ASPC).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation, Merck Sharp & Dohme Corporation, and AstraZeneca.

DATE OF RELEASE/EXPIRATION

October 20, 2020 – October 20, 2021

TARGET AUDIENCE

The educational design of this activity addresses the needs of cardiologists, nephrologists, primary care physicians, internists, nurse practitioners, physician assistants, pharmacists, and nurses involved in the management and treatment of patients with heart failure.

STATEMENT OF NEED/PROGRAM OVERVIEW

Despite advances in heart failure (HF) treatment during the past decade, this disease remains associated with high rates of morbidity, hospitalizations, and mortality, in addition to marked health care costs. Although women with HF live longer than men, they have a poorer quality and worse signs and symptoms of the disease. Women with HF also receive suboptimal treatment compared with men, illustrating a remediable disparity in care.

The evaluation and treatment of patients diagnosed with HF with reduced ejection fraction (HFrEF) represents a great challenge in both the general population and among elderly individuals who are the most vulnerable to this difficult-to-treat condition, partly because of the large number of associated comorbidities that such patients present with. Diagnosis of HF in women is also challenging because of its presentation. Uptake and optimization of HF pharmacotherapies is poor overall and is markedly low for newest agents. Disease-modifying medications have limited efficacy among people with heart failure with preserved ejection fraction (HFpEF). Fortunately, research is rapidly emerging on novel therapies for both HFpEF and HFrEF, and recently, anti-diabetes agents have shown cardiovascular (CV) benefits.

This educational initiative addresses guideline-concordant approaches to promote guideline-concordant treatment of HF and optimization of pharmacotherapy. Outcome analyses from a 2019 education series held by PQHE found that while the vast majority of respondents reported improved understanding or behavior change regarding the learning objectives, many participants could still not identify guideline-concordant therapies in case-based questions. Thus, an improved understanding of treatment guidelines, latest clinical trial data in a variety of patients populations with HF, including women and those with HFpEF, and enhanced ability to address barriers to guideline-directed medical therapy for HF are clearly needed among cardiologists, cardiology allied health professionals, and primary care physicians to reduce mortality rates and improve quality of life of people with HF.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TERM OF OFFERING

This activity was released on October 20, 2020 and is valid for 12 months. Requests for credit must be made no later than October 20, 2021.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

SYSTEM REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
James L. Januzzi, MD
Hutter Family Professor of Medicine, Harvard Medical School
Cardiology Division, Massachusetts General Hospital
Boston, MA
Consultant/Independent Contractor:
Abbott Laboratories, Novartis, Janssen Pharmaceutica, Roche

Grant/Research Support:
Novartis, Roche

Other/Royalty:
Endpoint Committees: Abbott Laboratories, AbbVie Inc., Amgen Inc., Bayer, CVRx, and Takeda Pharmaceutical Company
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Division Chief of Cardiology
University of Arizona-Phoenix-Professor of Medicine
Phoenix, AZ
Nothing to disclose
Alison L. Bailey, MD, FACC, FAACVPR
Chief of Cardiology
Centennial Heart at Parkridge HCA Healthcare,
Chattanooga, TN
Advisory Board: Bayer Pharmaceutics company

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Bridget Griffin Nothing to disclose

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.

Heart Failure – From Prognostic Modeling to Therapy in Patient with HFrEF


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Incorporate the recent updates from the 2017 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure into clinical practice
  • Recognize the multiple barriers that hinder the application of guideline-directed medical therapy in patients with HF
  • Provide optimal therapeutic dosing of recently introduced options to enhance health outcomes in patients with HF
  • Identify risk factors for significant morbidity and mortality that are associated with HF, particularly post hospitalization

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Novartis.

TUITION

Complimentary

Jointly Accredited Provider Logo





JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
September 20, 2019 from 11:00 AM EDT – 1:00 PM EDT.

Enduring Material
The enduring material will be available from September 20, 2019 to March 20, 2020.

TARGET AUDIENCE

This activity is intended for cardiologists, interventional cardiologists, primary care physicians, internists, advanced practitioners (nurse practitioners, physician assistants), pharmacists, and other health care providers who care for patients with heart failure.

ESTIMATED TIME TO COMPLETE

This activity consists of two sessions which should take approximately 2 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.CardioCareLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
James L. Januzzi, Jr., MD, FACC, FESC
Physician, Cardiology Division
Director, Dennis and Marilyn Barry Fellowship in Cardiology Research
Massachusetts General Hospital
Hutter Family Professor of Medicine in the Field of Cardiology
Harvard Medical School
Cardiometabolic Faculty
Baim Institute for Clinical Research
Consulting Fees: Novartis, Janssen, Boehringer-Ingelheim, Roche
Contracted Research: Novartis, Roche
Gregg C. Fonarow, MD, FACC, FAHA, FHFSA
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Chief, UCLA Division of Cardiology
Co-Director, UCLA Preventative Cardiology Program
David Geffen School of Medicine at UCLA
Consulting Fees: Novartis, Medtronic, Amgen, Janssen, Abbott
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Novartis
Contracted Research: NIH
Nasrien E. Ibrahim, MD, FACC, FHFSA
Assistant Professor of Medicine
Harvard Medical School
Advanced Heart Failure and Transplant Cardiologist
Massachusetts General Hospital
None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Joe Chebli Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.